Monoclonal Anti-ZFP36/TTP antibody produced in mouse

Monoclonal Anti-ZFP36/TTP antibody has been used in immunoblotting.

ZFP36 (also known as tristetraprolin or TTP) participates in controlling the expression of AU-rich element (ARE) -containing mRNAs. It participates in accelerating mRNA decay. ZFP36 was found to limit the expression of a number of critical genes frequently overexpressed in inflammation and cancer. It also plays a major role in differentiation, reprogramming, metabolism, proliferation, pluripotency, tumorigenesis and immunity.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Monoclonal Anti-ZFP36/TTP (mouse IgM isotype) is derived from the hybridoma TTP6 produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with a peptide corresponding to an internal sequence of human ZFP36/TTP, conjugated keyhole limpet hemocyanin (KLH). ZFP36 (also known as tristetraprolin or TTP) is a RNA-binding protein. It belongs to the RNA-binding zinc-finger protein family. TTP consists of a cysteine-cysteine-cysteine-histidine (CCCH) zinc finger motif and uridine-rich elements (AREs) in the 3′ untranslated region (3′ UTR) of target mRNA. This gene is located on human chromosome 19q13.1.

a peptide corresponding to an internal sequence of human ZFP36/TTP conjugated KLH.

Solution in Dulbecco′s Modified Eagle′s Medium with 10% fetal calf serum and 15 mM sodium azide.